HHC Banned in France: Back to the June 2023 Decision

On 13 June 2023, the ANSM listed HHC as a narcotic. Why, how, and what it means for consumers.

HHC Banned in France: Back to the June 2023 Decision

On 13 June 2023, the French national medicines agency ANSM listed HHC (hexahydrocannabinol) and two derivatives as narcotics. Fast decision, reasoned, no suspensive appeal.

What is HHC?

HHC is a semi-synthetic cannabinoid obtained by hydrogenation of CBD or THC. It is not naturally present in hemp in significant amounts. From 2022-2023, European markets saw HHC flowers, e-liquids and resins sold as "legal alternatives" to cannabis. Reported psychoactive effects close to or stronger than THC. Marketing presentation — often mimicking the aesthetics of cannabis flowers — blurred the line between regulated CBD and recreational-effect molecules.

Why the ban

  • Psychoactive effect — comparable to THC, justifying narcotic status under the 1971 Convention's general framework.
  • Lack of toxicology data — few studies on long-term effects, driving impact, drug interactions or use during pregnancy.
  • Rising reports — addiction monitoring centres and emergency services flagged adverse cases including anxiety, vomiting and acute intoxication.
  • Marketing concerns — products often presented as "legal cannabis", potentially misleading consumers about both legality and effects.

Timeline

  • 13 June 2023 — ANSM decision published in the Journal officiel.
  • Immediate effect — ban on manufacture, import, sale, possession, use.
  • Summer 2023 — DGCCRF inspections, HHC products seized.
  • Autumn 2023 — first criminal convictions for use and possession.
  • 2024 — extension to other semi-synthetics (H4CBD, HHCP).
  • 2025 — ANSM updates the list regularly, in coordination with the national pharmacovigilance reporting system.

Consequences for consumers

Holding HHC in France is now treated as narcotic use, aligned with classic cannabis rules. Returning or destroying remaining stock is the sensible path. Possession in another EU country where HHC is still legal does not carry the same penalties, but crossing the French border switches the regime. The same rule applies online: ordering an HHC product from a non-French website and having it delivered into France exposes the buyer to customs seizure and a narcotic use procedure.

European context

Several countries followed France: Belgium, Sweden, Finland, Italy. Others remain unclear. The EMCDDA published technical reports in 2023-2024 on the spread of semi-synthetic cannabinoids. EU-level harmonisation is still pending.

Industry impact

The HHC ban abruptly ended business for shops centred on the molecule. Several HHC-focused outlets closed in 2023-2024. Conversely, shops that stayed on natural cannabinoids saw loyal customer bases strengthen — many consumers grasped that stable rules beat uncertain psychoactivity. Most operators learned the lesson: second-rank semi-synthetics (HHCO, synthetic THCV, HHCP) never gained the same commercial traction post-2024.

Health angle

Pharmacovigilance cases were published in 2023-2024: anxiety attacks, vomiting, road accidents linked to HHC. The clinical profile approaches that of "spice"-type synthetic cannabinoids. Public health weighed in the ANSM decision alongside addiction monitoring pressure.

The Horus stance

We never listed HHC, before or after the ban. Our catalogue is limited to cannabinoids naturally present in legal hemp — CBD, CBG, CBN, CBC in trace, and THC below the legal threshold. This line, held in Boulogne-sur-Gesse and L'Isle-en-Dodon, spares us from sudden bans on semi-synthetics.

Further reading: H4CBD banned in 2024: why.

This article is for informational purposes only. For legal advice, consult a lawyer. CBD is not a medicine.

Discover our hand-picked CBD selection

Premium flowers, hashes & oils — sourced for taste, finish and aroma. Never lowest price first.

Browse the shop

Information for educational purposes only. CBD is not a medicine. In case of doubt, consult a healthcare professional. Sale prohibited to minors.